Minghui Pharmaceutical Presents Compelling Phase I/II Results for MHB018A, a Novel Subcutaneous Anti-IGF-1R Antibody for Thyroid Eye Disease, in an Oral Presentation at ENDO 2026, the Endocrine Society’s Annual Meeting

MHB018A demonstrated outstanding clinical activity in both active and chronic thyroid eye diseaseAt 450 mg Q4W, MHB018A achieved a remarkable 81% proptosis response at Week 12 in active TED and a 76% proptosis response at Week 24 in…

Read the full release →

News provided by PR Newswire.